Can platelet size predict severity and mortality in COVID-19?

Sumary of Can platelet size predict severity and mortality in COVID-19?:

  • The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has baffled researchers with its propensity to cause symptoms of largely unpredictable severity in the affected individuals.
  • While most patients have mild or no symptoms, a significant minority develop severe or critical symptoms, and some have a fatal outcome.
  • COVID-19 patients with severe disease often develop clots in vital organs, which leads to further complications.
  • Recently released onto the medRxiv* preprint server, the study shows that platelet-large cell ratio (P-LCR) is a key signal of platelet activity in COVID-19, detectable at the point of admission, and could well triage high-risk patients before they develop thrombotic complications.
  • Platelet aggregation is also increased, with elevated levels of thromboxane, a pro-inflammatory procoagulant molecule.
  • In fact, a consistent fall in platelets is linked to higher mortality in this condition.
  • COVID-19 patients with acute lung injury (ALI) show increased pulmonary megakaryocytes.
  • Younger platelets are larger and more active, indicating a higher risk of thrombosis.

Want to know more click here go to source.

From -

Generic selectors
Exact matches only
Search in title
Search in content

Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.